News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
33,018 Results
Type
Article (1287)
Company Profile (2)
Press Release (31729)
Section
Business (15434)
Career Advice (98)
Deals (1944)
Drug Development (3696)
FDA (519)
Job Trends (677)
News (20593)
Policy (1008)
Tag
Academia (46)
Accelerated approval (1)
Adcomms (1)
Allergies (4)
Alliances (1079)
ALS (5)
Alzheimer's disease (69)
Antibody-drug conjugate (ADC) (1)
Approvals (540)
Artificial intelligence (6)
Automation (1)
Bankruptcy (14)
Best Places to Work (659)
BIOSECURE Act (1)
Biosimilars (5)
Biotechnology (3)
Bladder cancer (12)
Breast cancer (15)
Cancer (158)
Cardiovascular disease (10)
Career advice (98)
CAR-T (3)
Cell therapy (9)
Cervical cancer (1)
Clinical research (3228)
Collaboration (31)
Compensation (4)
COVID-19 (64)
CRISPR (1)
C-suite (2)
Cystic fibrosis (3)
Data (236)
Depression (6)
Diabetes (17)
Diagnostics (273)
Digital health (3)
Drug discovery (7)
Drug pricing (2)
Duchenne muscular dystrophy (7)
Earnings (13907)
Events (4844)
Executive appointments (13)
FDA (657)
Frontotemporal dementia (1)
Funding (16)
Gene editing (1)
Generative AI (1)
Gene therapy (11)
GLP-1 (27)
Government (93)
Guidances (64)
Healthcare (888)
Huntington's disease (1)
IgA nephropathy (6)
Immunology and inflammation (7)
Indications (5)
Infectious disease (75)
Inflammatory bowel disease (3)
Influenza (3)
Intellectual property (3)
Interviews (9)
IPO (1451)
Job creations (55)
Job search strategy (94)
Labor market (2)
Layoffs (14)
Legal (148)
Liver cancer (3)
Lung cancer (30)
Lymphoma (20)
Manufacturing (6)
MASH (8)
Medical device (797)
Medtech (797)
Mergers & acquisitions (521)
Metabolic disorders (43)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (101)
NextGen: Class of 2025 (183)
Non-profit (59)
Now hiring (1)
Obesity (22)
Opinion (3)
Ovarian cancer (2)
Pain (5)
Pancreatic cancer (9)
Parkinson's disease (6)
Patents (12)
Patient recruitment (5)
Peanut (2)
People (1055)
Pharmacy benefit managers (1)
Phase I (715)
Phase II (1335)
Phase III (1414)
Pipeline (287)
Policy (1)
Postmarket research (182)
Preclinical (311)
Press Release (1)
Prostate cancer (7)
Psychedelics (4)
Radiopharmaceuticals (5)
Rare diseases (13)
Real estate (145)
Regulatory (864)
Reports (5)
Research institute (44)
Resumes & cover letters (5)
RSV (5)
Schizophrenia (8)
Series A (2)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (2)
Startups (82)
Supply chain (1)
Vaccines (13)
Venture capital (1)
Weight loss (9)
Women's health (2)
Date
Today (5)
Last 7 days (31)
Last 30 days (142)
Last 365 days (2107)
2025 (1094)
2024 (2310)
2023 (2522)
2022 (2764)
2021 (2908)
2020 (2353)
2019 (1780)
2018 (1322)
2017 (1101)
2016 (786)
2015 (1160)
2014 (736)
2013 (443)
2012 (514)
2011 (556)
2010 (581)
Location
Africa (101)
Alabama (4)
Arizona (12)
Arkansas (1)
Asia (2216)
Australia (265)
California (485)
Canada (141)
China (33)
Colorado (36)
Connecticut (27)
Delaware (18)
Europe (3998)
Florida (70)
Georgia (19)
Illinois (36)
India (1)
Indiana (33)
Japan (18)
Kansas (4)
Kentucky (1)
Louisiana (5)
Maine (6)
Maryland (54)
Massachusetts (322)
Michigan (15)
Minnesota (26)
Missouri (4)
Montana (3)
Nevada (4)
New Hampshire (6)
New Jersey (188)
New Mexico (1)
New York (113)
North Carolina (84)
Northern California (222)
Ohio (12)
Pennsylvania (118)
Puerto Rico (1)
South America (108)
South Carolina (1)
Southern California (179)
Tennessee (5)
Texas (44)
United States (1807)
Utah (18)
Virginia (8)
Washington D.C. (3)
Washington State (60)
Wisconsin (4)
33,018 Results for "104".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
June 25, 2025
·
9 min read
Press Releases
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
July 9, 2025
·
12 min read
Press Releases
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
June 16, 2025
·
1 min read
Press Releases
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
April 9, 2025
·
8 min read
Press Releases
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
May 19, 2025
·
4 min read
Press Releases
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
June 17, 2025
·
8 min read
Press Releases
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
May 5, 2025
·
6 min read
Press Releases
Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan
June 23, 2025
·
2 min read
Press Releases
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
May 5, 2025
·
13 min read
Press Releases
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
May 7, 2025
·
7 min read
1 of 3,302
Next
